» Articles » PMID: 7030200

Comparison of Ceftazidime and Cefamandole Pharmacokinetics and Blister Fluid Concentrations

Overview
Specialty Pharmacology
Date 1981 Sep 1
PMID 7030200
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Eight healthy male volunteers received 1 g of either ceftazidime or cefamandole as an intravenous infection. Serial blood samples were taken over the next 8 h. Urine samples were collected over 24 h. Levels of these antibiotics were measured in the fluid of blisters resulting from application of cantharides. The concentration of ceftazidime in serum at 0.25 h after intravenous injection was 83.3 micrograms/ml. The serum half-lives for the respective drugs were 1.8 and 0.8 h. The mean apparent volume of distribution of ceftazidime (13.6 liters) was greater than that of cefamandole (9.8 liters). Plasma clearance was 111 ml/min for ceftazidime and 216 ml/min for cefamandole. The maximum blister fluid concentration of ceftazidime was 45.9 micrograms/ml, and that of cefamandole was 22.1 micrograms/ml. The relative availability of each drug in blister fluid compared with serum was similar.

Citing Articles

Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.

Hajdu S, Holinka J, Reichmann S, Hirschl A, Graninger W, Presterl E Antimicrob Agents Chemother. 2010; 54(10):4078-84.

PMID: 20679509 PMC: 2944596. DOI: 10.1128/AAC.00275-10.


Population pharmacokinetic comparison and pharmacodynamic breakpoints of ceftazidime in cystic fibrosis patients and healthy volunteers.

Bulitta J, Landersdorfer C, Huttner S, Drusano G, Kinzig M, Holzgrabe U Antimicrob Agents Chemother. 2010; 54(3):1275-82.

PMID: 20065059 PMC: 2826012. DOI: 10.1128/AAC.00936-09.


Pharmacokinetics of cefpiramide (SM-1652) in humans.

Nakagawa K, Koyama M, Matsui H, Ikeda C, Yano K, Nakatsuru N Antimicrob Agents Chemother. 1984; 25(2):221-5.

PMID: 6712202 PMC: 185478. DOI: 10.1128/AAC.25.2.221.


Cephalosporins in gram-positive infections.

Symonds J, Geddes A Drugs. 1987; 34 Suppl 2:121-34.

PMID: 3319496 DOI: 10.2165/00003495-198700342-00010.


Comparative pharmacokinetics of ceftazidime in young, healthy and elderly, acutely ill males.

Ljungberg B Eur J Clin Pharmacol. 1988; 34(2):179-86.

PMID: 3289950 DOI: 10.1007/BF00614556.


References
1.
Wise R, Gillett A, Cadge B, Durham S, Baker S . The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics. J Infect Dis. 1980; 142(1):77-82. DOI: 10.1093/infdis/142.1.77. View

2.
OCALLAGHAN C, Acred P, Harper P, Ryan D, Kirby S, Harding S . GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob Agents Chemother. 1980; 17(5):876-83. PMC: 283891. DOI: 10.1128/AAC.17.5.876. View

3.
Wise R, Andrews J, Bedford K . Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob Agents Chemother. 1980; 17(5):884-9. PMC: 283892. DOI: 10.1128/AAC.17.5.884. View

4.
Fong I, Ralph E, Engelking E, KIRBY W . Clinical pharmacology of cefamandole as compared with cephalothin. Antimicrob Agents Chemother. 1976; 9(1):65-9. PMC: 429475. DOI: 10.1128/AAC.9.1.65. View

5.
Greenblatt D . Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med. 1975; 293(14):702-5. DOI: 10.1056/NEJM197510022931406. View